MidWest Eye Center first in Ohio, among first in the Midwest to implement Alcon's Voyager DSLT

Stephan Dixon, MD, standing next to the MidWest Eye Center's Voyager DSLT device. Image credit: MidWest Eye Center

The MidWest Eye Center (MWEC) has announced that it is the first in Ohio and among the first in the Midwest to implement the Alcon Voyager Direct Selective Laser Trabeculoplasty (DSLT) treatment for glaucoma and ocular hypertension.¹ Stephan G. Dixon, MD; Stephen Kondash, MD; and Sean Davitt, MD, were the first surgeons to implement the new technology into MWEC’s practice, according to a news release.

“Glaucoma, a progressive eye disease, impacts millions of people throughout our country and is also a leading cause of blindness worldwide,” said Dixon, glaucoma specialist at MWEC, in the release. “Early intervention is key and having access to sophisticated treatment options like Voyager Direct Selective Laser Trabeculoplasty is a game changer for our patients. This new technology offers a safer, faster, and more comfortable experience. By introducing patient-friendly innovations, we’re redefining the standard approach to managing and treating degenerative vision conditions for those we serve in the greater Cincinnati community – reflecting MidWest Eye Care’s ongoing commitment to provide advanced vision services, innovative solutions, and quality patient-focused care.”

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork. Therefore, direct eye contact, a gonioscopy lens, and a slit lamp are not needed for procedures that utilize the technology.¹ A randomized, controlled trial found that DSLT effectively controls intraocular pressure and has a strong safety profile. Additionally, 62% of DSLT participants in the trial were medication-free in 12 months, with nearly all patients reporting after 6 months that they would recommend the treatment to a friend with glaucoma.²

Another ophthalmologist practicing in the Midwest who has implemented the Voyager into his practice is Inder Paul Singh, MD. “I have been using Voyager DSLT since October of 2024, and it has made an incredible impact on the use of SLT for my practice,” said Singh, president of The Eye Centers of Racine and Kenosha, Wisconsin, in an Alcon news release.² “My patients have been delighted by the efficiency, comfort level of the treatment, and overall experience. Voyager DSLT has been embraced by my staff and is easy to implement, allowing me to treat more of my patients with a recognized first-line standard in glaucoma treatment.”

The DSLT technology has been fully commercially available in the US since February 2025.²

References:

1. MidWest Eye Center first in Ohio and among first in the region to offer Alcon’s new DSLT glaucoma technology. News release. MidWest Eye Center. July 10, 2025. Accessed July 10, 2025.

2. Alcon announces US launch of Voyager DSLT, first-of-its-kind treatment for glaucoma and ocular hypertension. News release. Alcon. February 19, 2025. Accessed July 10, 2025. https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Announces-U.S.-Launch-of-Voyager-DSLT-First-of-its-Kind-Treatment-for-Glaucoma-and-Ocular-Hypertension/default.aspx